Targeting Key Signalling Pathways in Oesophageal Adenocarcinoma: a Reality for Personalised Medicine?

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2011 Jul 8

PMID 21734785

Citations 5

Authors

Richard R Keld

Yeng S Ang

Affiliations

Soon will be listed here.

Abstract

Cancer treatments are rapidly changing. Curative treatment for oesophageal adenocarcinoma currently involves surgery and cytotoxic chemotherapy or chemoradiotherapy. Outcomes for both regimes are generally poor as a result of tumor recurrence. We have reviewed the key signalling pathways associated with oesophageal adenocarcinomas and discussed the recent trials of novel agents that attempt to target these pathways. There are many trials underway with the aim of improving survival in oesophageal cancer. Currently, phase 2 and 3 trials are focused on MAP kinase inhibition, either through inhibition of growth factor receptors or signal transducer proteins. In order to avoid tumor resistance, it appears to be clear that targeted therapy will be needed to combat the multiple signalling pathways that are in operation in oesophageal adenocarcinomas. This may be achievable in the future with the advent of gene signatures and a combinatorial approach.

Citing Articles

An evolutionary differential game for regulating the role of monoclonal antibodies in treating signalling pathways in oesophageal cancer.

Alajmi M, Roy S R Soc Open Sci. 2024; 11(7):240347.

PMID: 39086820 PMC: 11289643. DOI: 10.1098/rsos.240347.

Inhibition of Wnt/β-Catenin Signaling Sensitizes Esophageal Cancer Cells to Chemoradiotherapy.

Spitzner M, Emons G, Schutz K, Wolff H, Rieken S, Ghadimi B Int J Mol Sci. 2021; 22(19).

PMID: 34638639 PMC: 8509072. DOI: 10.3390/ijms221910301.

Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma.

Toxopeus E, Lynam-Lennon N, Biermann K, Dickens G, de Ruiter P, van Lanschot J Exp Biol Med (Maywood). 2019; 244(14):1210-1219.

PMID: 31390899 PMC: 6802158. DOI: 10.1177/1535370219868671.

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.

Hou X, Du H, Quan X, Shi L, Zhang Q, Wu Y Front Pharmacol. 2018; 9:21.

PMID: 29472856 PMC: 5809401. DOI: 10.3389/fphar.2018.00021.

Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.

Ong C, Shapiro J, Nason K, Davison J, Liu X, Ross-Innes C J Clin Oncol. 2013; 31(12):1576-82.

PMID: 23509313 PMC: 3625712. DOI: 10.1200/JCO.2012.45.9636.

References

Albino A, Le Strange R, Oliff A, Furth M, Old L . Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?. Nature. 1984; 308(5954):69-72. DOI: 10.1038/308069a0. View

Pinedo H, Peters G . Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988; 6(10):1653-64. DOI: 10.1200/JCO.1988.6.10.1653. View

Gibson M, Abraham S, Wu T, Burtness B, Heitmiller R, Heath E . Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res. 2003; 9(17):6461-8. View

Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T . Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol. 2006; 24(26):4309-16. DOI: 10.1200/JCO.2005.04.2424. View

Ferry D, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J . A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res. 2007; 13(19):5869-75. DOI: 10.1158/1078-0432.CCR-06-1970. View

Cooper G, Kou T, Chak A . Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol. 2009; 104(6):1356-62. DOI: 10.1038/ajg.2009.159. View

Polee M, Hop W, Kok T, Eskens F, van der Burg M, Splinter T . Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003; 89(11):2045-50. PMC: 2376851. DOI: 10.1038/sj.bjc.6601364. View

Wang V, Hornick J, Sepulveda J, Mauer R, Poneros J . Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest Endosc. 2009; 69(4):777-83. DOI: 10.1016/j.gie.2008.05.013. View

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4):337-45. DOI: 10.1056/NEJMoa033025. View

10.

Robinson D, Wu Y, Lin S . The protein tyrosine kinase family of the human genome. Oncogene. 2000; 19(49):5548-57. DOI: 10.1038/sj.onc.1203957. View

11.

. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 359(9319):1727-33. DOI: 10.1016/S0140-6736(02)08651-8. View

12.

Yousef F, Cardwell C, Cantwell M, Galway K, Johnston B, Murray L . The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008; 168(3):237-49. DOI: 10.1093/aje/kwn121. View

13.

Tuynman J, Lagarde S, Ten Kate F, Richel D, van Lanschot J . Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 2008; 98(6):1102-8. PMC: 2275481. DOI: 10.1038/sj.bjc.6604251. View

14.

Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lupfert C . Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer. 2009; 99(6):868-74. PMC: 2538760. DOI: 10.1038/sj.bjc.6604622. View

15.

Clement G, Jablons D, Benhattar J . Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets. 2007; 11(3):375-89. DOI: 10.1517/14728222.11.3.375. View

16.

Rubenstein J, Sonnenberg A, Davis J, McMahon L, Inadomi J . Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc. 2008; 68(5):849-55. PMC: 3481546. DOI: 10.1016/j.gie.2008.02.062. View

17.

Solaymani-Dodaran M, Logan R, West J, Card T, Coupland C . Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut. 2004; 53(8):1070-4. PMC: 1774141. DOI: 10.1136/gut.2003.028076. View

18.

Abdel-Latif M, Kelleher D, Reynolds J . Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J Surg Res. 2008; 153(1):172-80. DOI: 10.1016/j.jss.2007.12.755. View

19.

Brozovic A, Osmak M . Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett. 2006; 251(1):1-16. DOI: 10.1016/j.canlet.2006.10.007. View

20.

Tan X, Egami H, Abe M, Nozawa F, Hirota M, Ogawa M . Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol. 2005; 58(12):1242-8. PMC: 1770786. DOI: 10.1136/jcp.2004.025338. View